Articles On Dimerix (ASX:DXB)

Dimerix (ASX:DXB) just delivered significant progress on its Phase III Clinical Trial for FSGS, with the first EU regulatory approval given for DXB’s kidney disease study in Denmark... earlier than expected.

Our 2021 Biotech Pick of the Year Dimerix (ASX:DXB) released its half year report last Thursday, updating investors on ethics approvals for its Phase III clinical trial for FSGS (a rare kidney disease) and closing in on important milestones...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Dimerix (ASX:DXB) has announced it has received an R&D Tax Incentive rebate of $3.695 million for the 2020-21 year.

International Women’s Day is a day to celebrate the achievements of women worldwide, who are breaking down barriers and building paths for others to follow but it also a time to reflect on what else needs to be done to ensure more glass cei...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

Dimerix’s study in COVID-19 patients in Europe is being adapted after the independent safety data monitoring board highlighted concerns with other treatment arms not connected to its lead compound DMX-200. Clinical stage biopharma Dimerix...

The ASX200 has come to a jerky halt, closing more than 50 points or 0.7% higher. The market is down 5.6% over the last 52 weeks. The ASX Emerging Companies (XEC) index ended 0.6% better. The Four Horsemen of the Apocalypse are abroad on Mon...

Disclosure: The authors of this article and owners of Finfeed , S3 Consortium Pty Ltd, and associated entities, own 2,825,000 DXB shares at the time of writing. S3 Consortium Pty Ltd has been engaged by DXB to share our commentary on the pr...

Dimerix (DXB) pauses recruitment of COVID-19 patients with COVID-19 for its clinical study after safety issues were observed in patients with severe COVID-19 The Independent Data Safety Monitoring Board’s (DSMB) scheduled interim safety as...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The company remains well-funded to advance its clinical development pathway, as it looks to execute on a lucrative market opportunity. Clinical-stage biopharma company Dimerix (ASX:DXB) released its half-year results this morning, accompani...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

Dimerix (ASX: DXB) has announced the appointment of Dr Ash Soman as chief medical officer and a member of its executive management team.

Disclosure: The authors of this article and owners of Finfeed, S3 Consortium Pty Ltd, and associated entities, own 2,825,000 DXB shares at the time of writing this article. S3 Consortium Pty Ltd has been engaged by DXB to share our commenta...

Two studies involving the use of DMX-200 are advancing rapidly, as part of global research efforts to develop improved treatment solutions for COVID-19 respiratory failure. For Dimerix (ASX:DXB), 2022 is shaping up as a busy year as it exec...

Today we announce the fourth addition to our portfolio for 2021. Today we are adding Dimerix (ASX:DXB) to the Next Investors portfolio as our inaugural Biotech Pick of the Year for 2021.

Dimerix (ASX:DXB) says the first patients have been dosed in the India-based CLARITY 2.0 feasibility/Phase 3 study of DMX-200 as a potential new treatment for respiratory complications associated with COVID-19.

Highlights The ASX 200 fell 0.39% or 28.7 points to 7,409.1 in the first five minutes of trading. The 10-year Treasury yield in the US hit a two-year high on Monday. Nine out of the 11 sectors were trading in the red zone. The Aus...

Biopharmaceutical company Dimerix (DXB) doses its first patients with its inflammatory disease treatment, DMX-200, in India The company is currently studying its DMX-200 as a potential new treatment for respiratory complications associate...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

Christmas has come early for Dimerix with Australian ethics approval granted for a Phase 3 clinical trial of its DMX-200 drug in COVID-19 patients with pneumonia respiratory complications. As the latest Omicron variant fuels COVID-19 cases...

Dimerix (DXB) has received Australian ethics approval for its phase three COVID-19 study, dubbed CLARITY 2.0 This approval is from the Research Ethics and Governance Office Ethics Committee and is for trialing DMX-200 in patients with COVI...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The further grant from the government will expedite the progress of Dimerix’ novel COVID-19 drug DMX-200 into possible commercialisation. Dimerix (ASX:DXB) has just received further funding from the Australian government  to support the com...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

Shareholders of Dimerix (ASX:DXB) got an early Christmas present with the company telling them its Phase 3 clinical trial testing its DMX-200 drug against COVID-19 pneumonia respiratory complications in Europe was on track. The study (REMAP...

The REMAP-CAP Data Safety Monitoring Board (DSMB) has recommended Dimerix (DXB) continues enrolments for its ACE2 renin angiotensin system (RAS) modulation study Dimerix has so far recruited 662 COVID-19 pneumonia patients in Europe with 4...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

We invested in Dimerix (ASX:DXB) in August for its fully funded Phase III clinical trials treating FSGS (a rare kidney disease) and its two near term Phase III trials for COVID-19. In early stage biotech investing, Phase III trials are the...

Dimerix (DXB) is granted Australian ethics and regulatory approval for its Phase 3 clinical trial in FSGS kidney patients The clinical trial will see the company evaluate the efficacy and safety of DMX-200 against a placebo in patients wit...

Dimerix is partnering with the NHMRC Clinical Trials Centre at the University of Sydney to expand a feasibility/phase 3 trial of its DMX-200 drug candidate to treat COVID-19 sufferers with respiratory complications.

The Dimerix Ltd (ASX: DXB) share price is gaining more field position in afternoon trade and is now changing hands at 28.5 cents. That’s an approximate 4% gain for the biopharmaceutical company today after it released a key update regardi...

Regular Finfeed readers should be familiar by now with Dimerix (ASX:DXB) - the first investment in our small cap ASX listed biotech portfolio. DXB has developed a treatment for inflammatory diseases, such as kidney and respiratory diseases....

Dimerix (DXB) enters an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.0 clinical study The study, which is already approved and recruiting in India, will recruit 600 patients across Ind...

Cronos Australia (ASX:CAU) jumped 7% this morning, after reporting significant growth in the sales of its Adaya medicinal cannabis range — up 90% from the previous quarter. Sales of Adaya for the first quarter have exceeded $1.1m, Cronos sa...

Today we announce the fourth addition to our portfolio for 2021. Today we are adding Dimerix (ASX:DXB) to the Next Investors portfolio as our inaugural Biotech Pick of the Year for 2021.

The capital structure for DXB’s marquee capital raise was signed off by shareholders at its AGM last month. ASX biotech Dimerix (ASX:DXB) closed out a big month on equity capital markets with an oversubscribed share purchase plan (SPP) last...

Clinical-stage drug development company Dimerix (ASX:DXB) has announced that the Indian regulator has formally recommended the approval of the study of DMX-200 in patients with COVID-19.

The Dimerix Ltd (ASX: DXB) share price is taking off today. Meanwhile, the company has conducted its annual general meeting (AGM). At the meeting, CEO Dr Nina Webster looked back on a year she described as “pivotal for the future of Dimeri...

Dimerix’s lead drug candidate DMX-200 has been given regulatory green light for approval for a Phase 3 study in COVID-19 ravaged India. Clinical-stage biotech Dimerix (ASX:DXB)  has received approval from the review committee in India for...

Our new business model is to research, analyse, and invest in up and coming small cap ASX-listed biotech stocks that we believe have a high chance of success. We then share our research and commentary along our investment journey with our r...

The broad Australian indices have started the day off in the red as the market resets from a number of stirrups this week. The S&P/ASX 200 index (ASX: XJO) has clipped 0.37% lower today and sits at 7,343 points, whereas the S&P/AS...

Shares in Dimerix Ltd (ASX: DXB) are soaring today, shooting up 9% in early trade. At the time of writing, the Dimerix share price has retreated slightly and is now trading at 30 cents apiece, up 7.4%. Below we take a look at the clinical-...

The ASX 200 health stocks index (XHJ) is down by 0.82% at the time of writing, compared to the broader ASX 200 index which is down by 0.08% Respiratory tech specialist, Adherium (ASX:ADR), jumped 12% this morning after saying it was awarded...

The placement gives Dimerix a flexible, long-term funding solution as the Phase 3 clinical trial kicks off with first ethics submission. For biopharmaceutical companies, securing new funding pathways for the development of complex clinical...

August was another month of lockdown for much of Australia’s East Coast but lockdowns and even a 2% drop in the middle of the month couldn’t stop the ASX from producing another winners list. The ASX 200 ultimately finished August 1.9% highe...

The Dimerix Ltd (ASX: DXB) share price is gaining today despite no news having been released by the company. In fact, the market hasn’t heard anything from Dimerix in more than a week. Right now, Dimerix’s shares are swapping hands for 35...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...